Private Sector Global Health R&D Project

Blog Posts

University of New England biomedical research lab manager Brittany Roy works in Ian Meng's laboratory in Biddeford

TechTank

Assessing the challenges, opportunities, and investment options in global health R&D

Jake Schneider

Tuesday, April 24, 2018

Ruth Munyao, a pharmacist, dispenses anti-retroviral (ARV) drugs at the Mater Hospital in Kenya's capital Nairobi, September 10, 2015. Most of the 3,000 patients at Mater Hospital's Comprehensive Care Clinic, dedicated to HIV/AIDS treatment, come from nearby shanty towns. In Kenya, HIV prevalence among adults has almost halved since the mid-1990s to 5.3 percent in 2014, according to UNAIDS. Yet HIV/AIDS remains the leading cause of death in Kenya, responsible for nearly three in 10 deaths in the east African country, where 1.6 million Kenyans are infected, government data in 2014 shows. Picture taken September 10, 2015. To match Special Series DEVELOPMENT-GOALS/KENYA-HEALTH REUTERS/Thomas Mukoya - GF10000201330

TechTank

How profitable are HIV drugs?

Jake Schneider and Darrell M. West

Monday, April 16, 2018

TechTank

Less than four percent of private investment in health R&D targets the developing world

Liz Sablich

Friday, April 6, 2018

View All Blog Posts

Events

Spurring private investment in health R&D around the world

10:00 AM - 11:30 AM EDT

Washington, DC

View All Events

Experts

Jeremy Barofsky

Non-resident Fellow - Governance Studies

John Villasenor

Nonresident Senior Fellow - Governance Studies, Center for Technology Innovation

JohnDVillasenor

Darrell M. West

Vice President and Director - Governance Studies

Senior Fellow - Center for Technology Innovation

Douglas Dillon Chair in Governmental Studies

@DarrWest

View All Experts

More on Private Sector Global Health R&D Project

Young scientists analyzing substances in laboratory

External Article

Assessing Pharma’s constraints, opportunities, and investment options in global health R&D: An analysis of SEC 10-K filings

Tuesday, April 24, 2018

Technician Matthew Smith loads a robotic DNA sample automation machine

TechTank

Five ways to improve private investment in global health R&D

Jake Schneider and Darrell M. West

Wednesday, March 28, 2018

A pharmacy employee looks for medication.

TechTank

Are drugs for neglected diseases profitable?

Jake Schneider and Jeremy Barofsky

Tuesday, December 19, 2017

View All

Private Sector Global Health R&D Project

Measuring revenue streams and profitability for HIV drugs

Private Sector Investment in Global Health R&D

Promoting private sector involvement in neglected tropical disease research and development

Health governance capacity

Blog Posts

Assessing the challenges, opportunities, and investment options in global health R&D

How profitable are HIV drugs?

Less than four percent of private investment in health R&D targets the developing world

Events

Spurring private investment in health R&D around the world

Experts

Jeremy Barofsky

Non-resident Fellow - Governance Studies

John Villasenor

Nonresident Senior Fellow - Governance Studies, Center for Technology Innovation

Darrell M. West

Vice President and Director - Governance Studies

Senior Fellow - Center for Technology Innovation

Douglas Dillon Chair in Governmental Studies

More on Private Sector Global Health R&D Project

Assessing Pharma’s constraints, opportunities, and investment options in global health R&D: An analysis of SEC 10-K filings

Five ways to improve private investment in global health R&D

Are drugs for neglected diseases profitable?